Biotech Firm Hit With Chancery Suit Over Stock Transactions
Industrial biotechnology company Amyris Inc. has been hit with a proposed class action in Delaware Chancery Court seeking to halt an upcoming vote on a stock conversion and $200 million stock...To view the full article, register now.
Already a subscriber? Click here to view full article